PROBLEM TO BE SOLVED: To provide methods for treating multiple sclerosis (MS) with Campath-1H with significant drug efficacy and a favorable safety profile, which offers an acceptable benefit/risk rate.SOLUTION: Described herein is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises dosing for 1-5 consecutive days, wherein 0<；daily dose≤12 mg, and each treatment cycle is separated from the next cycle by at least 1-24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.SELECTED DRAWING: None【課題】顕著な薬効及び有益な安全性プロファイルを有し、許容可能な効果／リスク比を示すカンパス（Campath-1H）による多発性硬化症（ＭＳ）の治療方法の提供。【解決手段】多発性硬化症（ＭＳ）治療用の医薬の製造のためのカンパス－１Ｈ（アレムツズマブ（alemtuzumab））の使用であって、第一治療サイクルと、それに続く少なくとも１回のカンパス－１Ｈ（アレムツズマブ）の追加治療サイクルを含んでなり、各治療サイクルは１～５回の連日投与を含んでなり、ここで０＜一日用量は≦12mgであり、また、各治療サイクルは、次のサイクルまで少なくとも１～24ヶ月の間隔があり、カンパス－１Ｈを12mg/日未満の用量で連続１～５日間投与することを含んでなる治療投薬計画。【選択図】なし
